Blood level check could make lung cancer drug work better

NCT ID NCT06195527

Recruiting now Knowledge-focused Sponsor: University Hospital, Angers Source: ClinicalTrials.gov ↗

First seen Jan 11, 2026 · Last updated Apr 29, 2026 · Updated 12 times

Summary

This study looks at 75 adults with non-small cell lung cancer who are receiving pembrolizumab (Keytruda). Researchers want to see if the amount of drug in a patient's blood is linked to how well the cancer shrinks or if side effects occur. By monitoring drug levels over time, they hope to find ways to personalize dosing and improve outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Angers University Hospital
RECRUITING

Angers, 49000, France

Contact Phone: •••-•••-•••• Email: •••••@•••••
CH Le Mans
NOT_YET_RECRUITING

Le Mans, 53000, France

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

NON SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER